Literature DB >> 22101613

Appraising osteoporosis care gaps.

Thomas P Olenginski1, Jana L Antohe, Elaine Sunderlin, Thomas M Harrington.   

Abstract

To evaluate physician response to dual-energy X-ray absorptiometry (DXA) report within the Geisinger Medical Center's Mobile DXA Program and treatment adherence at 1 year. Between 10/01/2004 and 3/30/2005, 1381 DXA scans were performed in our Mobile DXA Program. Within this cohort, we identified 366 high-risk, drug-naive patients and report the percentage of patients placed on prescription drug therapy within 90 days of DXA result. Additionally, we identified 191 patients with Z-score of -1.0 or worse and report whether laboratory tests were ordered within 90 days of DXA results in this group. Finally, we determined treatment adherence at 1 year. 269 patients (74%) were offered prescription therapy within 3 months of DXA results. Of those, 210 (57%) were still adherent to drug therapy at 1 year. The main reason for discontinuation of treatment was an adverse drug side effect. Additionally, in 50% cases, physicians ordered 1 or more laboratory tests to evaluate low Z-score. Within our Mobile DXA Program, 74% of high-risk, drug-naïve patients were treated. Interestingly, in 50% cases, when a low Z-score was reported, our physicians ordered 1 or more laboratory tests. Treatment adherence was 57% at 1 year.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22101613     DOI: 10.1007/s00296-011-2203-5

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  33 in total

1.  A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.

Authors:  C H Chesnut; S Silverman; K Andriano; H Genant; A Gimona; S Harris; D Kiel; M LeBoff; M Maricic; P Miller; C Moniz; M Peacock; P Richardson; N Watts; D Baylink
Journal:  Am J Med       Date:  2000-09       Impact factor: 4.965

2.  Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

Authors:  Russel Burge; Bess Dawson-Hughes; Daniel H Solomon; John B Wong; Alison King; Anna Tosteson
Journal:  J Bone Miner Res       Date:  2007-03       Impact factor: 6.741

3.  Evaluation of osteoporosis treatment in seniors after hip fracture.

Authors:  A G Juby; C M De Geus-Wenceslau
Journal:  Osteoporos Int       Date:  2002-03       Impact factor: 4.507

4.  Osteoporosis intervention following distal forearm fractures: a missed opportunity?

Authors:  Maria-Teresa Cuddihy; Sherine E Gabriel; Cynthia S Crowson; Elizabeth J Atkinson; Claudia Tabini; W Michael O'Fallon; L Joseph Melton
Journal:  Arch Intern Med       Date:  2002-02-25

5.  Primary care house staff attitudes toward osteoporosis management.

Authors:  Terry A McNearney; Angela J Shepherd; Ajoy Chhabra; Niti Goel
Journal:  South Med J       Date:  2006-05       Impact factor: 0.954

6.  Incidental vertebral fractures discovered with chest radiography in the emergency department: prevalence, recognition, and osteoporosis management in a cohort of elderly patients.

Authors:  Sumit R Majumdar; Nancy Kim; Ian Colman; Anthony M Chahal; Gregory Raymond; Ho Jen; Kerry G Siminoski; David A Hanley; Brian H Rowe
Journal:  Arch Intern Med       Date:  2005-04-25

7.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

8.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

9.  The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study.

Authors:  A Papaioannou; C C Kennedy; G Ioannidis; Y Gao; A M Sawka; D Goltzman; A Tenenhouse; L Pickard; W P Olszynski; K S Davison; S Kaiser; R G Josse; N Kreiger; D A Hanley; J C Prior; J P Brown; T Anastassiades; J D Adachi
Journal:  Osteoporos Int       Date:  2007-10-09       Impact factor: 4.507

Review 10.  High prevalence of vitamin D inadequacy and implications for health.

Authors:  Michael F Holick
Journal:  Mayo Clin Proc       Date:  2006-03       Impact factor: 7.616

View more
  3 in total

1.  High-risk osteoporosis clinic (HiROC): improving osteoporosis and postfracture care with an organized, programmatic approach.

Authors:  T P Olenginski; G Maloney-Saxon; C K Matzko; K Mackiewicz; H L Kirchner; A Bengier; E D Newman
Journal:  Osteoporos Int       Date:  2014-11-15       Impact factor: 4.507

2.  Geisinger high-risk osteoporosis clinic (HiROC): 2013-2015 FLS performance analysis.

Authors:  P Dunn; D Webb; T P Olenginski
Journal:  Osteoporos Int       Date:  2017-10-23       Impact factor: 4.507

3.  Associations between the 2007 Medicare reimbursement reduction for bone mineral density testing and osteoporosis drug therapy patterns of female Medicare beneficiaries.

Authors:  Sun Jung Kim; Joo Hun Lee; Sulgi Kim; Shunichi Nakagawa; Heather Bertelson; Julia Lam; Ji Won Yoo
Journal:  Patient Prefer Adherence       Date:  2014-06-25       Impact factor: 2.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.